News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Investors Elated as Relypsa (RLYP)'s Phase IV Study of Veltassa Successful 8/31/2016
Rigel (RIGL)'s Bleeding Disorder Drug Passes First of Two Key Late-Stage Trials 8/30/2016
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016
Marathon Pharma Announces Neurology Publication Of Pivotal Phase III Data For Deflazacort For Duchenne Muscular Dystrophy 8/30/2016
Portola (PTLA) Announces Interim Results From Ongoing Phase IIIb/IV ANNEXXA-4 Study Of Factor Xa Inhibitor Antidote Andexxa (Andexanet Alfa) In Patients With Acute Major Bleeding 8/30/2016
SAGE Therapeutics (SAGE) And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics 8/30/2016
SIGA (SIGA) Announces Completion Of Enrollment And Dosing In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat) 8/30/2016
Regeneron (REGN), Sanofi (SNY)'s Potential Blockbuster Praluent Passes Late-Stage Test 8/30/2016
Amgen (AMGN) Announces Positive Top-Line Results From Phase 3 Study Of Prolia (Denosumab) In Patients Receiving Glucocorticoid Therapy 8/29/2016
AcelRx (ACRX) Presents Results From Phase 3 Study Of ARX-04 In The Emergency Department At The International Society For Burn Injuries 8/29/2016
CTI BioPharma's Pacritinib Shows Mixed Results in Phase III Test; Full Clinical Hold Still In Effect 8/29/2016
Nymox (NYMX)'s New Phase III Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show 8/29/2016
Taking a Closer Look at Nymox (NYMX)'s 'Overinflated' Prostate Drug Hype 8/29/2016
Adocia's Foot Ulcer Med Flunks Phase III Test 8/26/2016
Novartis AG (NVS) Touts Phase III Data for MS Drug Siponimod 8/25/2016
Sunesis (SNSS) Announces Publication in "Drugs" Detailing Molecular And Pharmacologic Properties Of Vosaroxin 8/25/2016
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016
INSYS Reports Phase III Trial Of Sublingual Buprenorphine Spray Met Primary Endpoint In Patients With Moderate-To-Severe Postoperative Pain After Bunionectomy 8/24/2016
Nymox Pharmaceutical (NYMX) Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction In Incidence Of Surgery 8/24/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture To Begin Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome In 3rd Quarter 8/24/2016
Inotek (ITEK) Announces The Completion Of The Recruitment Phase Of MATrX-1, The First Phase 3 Clinical Trial Of Trabodenoson For Glaucoma 8/24/2016
DalCor Announces Opening Of International Trial Sites For Its Dal-Gene Phase 3 Cardiovascular Outcomes Trial 8/23/2016
Galapagos (GLPG.BR) Release: Finch Filgotinib Phase 3 Program Initiated In Rheumatoid Arthritis 8/23/2016
Eli Lilly (LLY)'s Incoming CEO May Carry First Alzheimer's Drug Across The Finish Line 8/22/2016
Eli Lilly (LLY) And AstraZeneca PLC (AZN) Receive FDA Fast Track Designation For AZD3293, An Investigational Treatment For Early Alzheimer's Disease 8/22/2016
Mezzion (140410.KQ) And NHLBI Initiate Enrollment In A Pivotal Phase 3 Clinical Trial Of Udenafil In Adolescents With Fontan Surgical Palliation - An Orphan Drug Indication 8/22/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
Auris Med (EARS)'s Tinnitus Drug Misses Main Goals in Study; Shares Sink 8/18/2016
Intercept Pharma (ICPT) Release: The New England Journal of Medicine Publishes Results Of Phase III POISE Trial Of Ocaliva (Obeticholic Acid) For The Treatment Of PBC 8/18/2016
Remedy Pharmaceuticals, Inc.’ Edema And Neuro-Inflammation Advisory Board Provides Guidance On Opportunities In CNS Conditions 8/18/2016
ARCA biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial 8/18/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study 8/17/2016
Indivior Shows Off Late-Stage Opiod Addiction Trial Data 8/17/2016
Cytokinetics (CYTK) Completes Enrollment In VITALITY-ALS, Phase III Clinical Trial Of Tirasemtiv In Patients With ALS 8/17/2016
OncoGenex (OGXI) Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study Fails 8/16/2016
Radius Health (RDUS) Release: JAMA Publishes Positive Phase 3 Data For Abaloparatide In Postmenopausal Women With Osteoporosis 8/16/2016
Primary Endpoint Met in pSivida (PSDV)’s First Medidur Phase III 8/16/2016
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
AcelRx (ACRX)' ARX-04 Phase 3 Trial Met its Primary Endpoint 8/15/2016
BeyondSpring Pharmaceuticals Announces First Patient Enrolled In China In A Global Phase 3 Trial Of Plinabulin For Non-Small Cell Lung Cancer 8/15/2016
Paratek Pharmaceuticals, Inc. Initiates Phase 3 Study Of Oral-Only Omadacycline In ABSSSI 8/15/2016
Ritter Pharmaceuticals, Inc. Completes Enrollment For Phase 2b/3 Trial Of RP-G28 In Lactose Intolerance 8/15/2016
Acacia Pharma Announces Positive Results From A Pivotal Phase 3 Trial Of BAREMSIS For The Treatment Of Post-Operative Nausea & Vomiting 8/12/2016
Spark Therapeutics (ONCE) Touts Long-Term Positive Phase III Gene Therapy Data 8/11/2016
Resverlogix (RVX.TO) Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 8/11/2016
Ascendis Pharma A/S Initiates Phase 3 Registration Trial For TransCon Growth Hormone In Children With Growth Hormone Deficiency 8/11/2016
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016
Nymox Pharmaceutical (NYMX) Announces Prostate Drug Progress 8/11/2016
ProMetic Life Sci (PFSCF.PK) Completes Patients' Enrolment In Pivotal Plasminogen Phase 2/3 Clinical Trial 8/11/2016
Eli Lilly (LLY)'s Breast Cancer Drug Failed to Meet Phase III Goals, But Panel Recommends Continuation of Trial 8/10/2016
AstraZeneca PLC (AZN)'s Lung Cancer Drug Flunks Late-Stage Test 8/10/2016
Eisai Company (ESALY.PK) Release: U.S. FDA Confirms Sufficient Data To Advance Investigational Bace Inhibitor E2609 For Treatment Of Early Alzheimer’s Disease To PHASE III 8/10/2016
AstraZeneca PLC (AZN) Announces Positive Top-Line Data From Two Phase III SYMBICORT Studies 8/10/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Announces Approvals To Start Phase 3 Study For MOB-015 In U.S. And Canada 8/10/2016
Results From Merck & Co. (MRK)’s Phase 3 Study Evaluating ZEPATIER (Elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C Receiving Treatment For Opioid Dependence Published In Annals Of Internal Medicine 8/9/2016
ProMetic Life Sci (PFSCF.PK) Completes Adult Patients' Enrolment In Pivotal IVIG Phase 3 Clinical Trial 8/9/2016
SIGA (SIGA) Announces Data Safety Monitoring Board (DSMB) Approval To Complete Subject Enrollment In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat) 8/9/2016
Akebia (AKBA) Initiates INNO2VATE Phase 3 Program For Vadadustat In Dialysis Patients With Anemia Related To Chronic Kidney Disease 8/9/2016
ThromboGenics NV (TBGNF) 2-Year OASIS Study Results Published In Ophthalmology, Journal Of The American Academy Of Ophthalmology (AAO) 8/8/2016
Pfizer (PFE) Announces Publication Of New Analysis Showing Long-Term Therapy With VYNDAQEL (Tafamidis) Slowed Progression Of Rare Neurodegenerative Disease 8/8/2016
Alnylam (ALNY) Completes Enrollment In ENDEAVOUR Phase III Study With Revusiran, An Investigational Rnai Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (Hattr-CM) 8/8/2016
Bristol-Myers Squibb (BMY)'s Failed Lung Cancer Data Sends Stock Plunging 8/5/2016
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study 8/5/2016
Allergan (AGN), Gedeon Richter (RIG2.F) Face Setback in Cariprazine Antidepressant Trial 8/5/2016
Amarin (AMRN) And FDA Reaffirm Concurrence On REDUCE-IT Through Special Protocol Assessment Agreement Amendment 8/4/2016
Anthera Pharma (ANTH)Announces Completion Of Dosing In CHABLIS-SC1 Phase III Clinical Study With Blisibimod 8/4/2016
Palatin Tech (PTN) Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 8/4/2016
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results 8/4/2016
FDA Bestows Novartis AG (NVS)'s Breast Cancer Pill With Breakthrough Tag 8/3/2016
ViroMed Approved To Start Trial Of Gene Therapy For Ischemic Heart Disease 8/3/2016
Mast Therapeutics (MSTX) Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer 8/3/2016
PharmaMar S.A. Initiates A Pivotal Phase III ATLANTIS Study With PM1183 In Combination With Doxorubicin In Patients With Small Cell Lung Cancer 8/2/2016
Takeda (TKPYY) And TiGenix Announce Publication In The Lancet Of 24-Week Results Of The Phase 3 ADMIRE-CD Trial Investigating Cx601 In The Treatment Of Complex Perianal Fistulas In Patients With Crohn's Disease 8/2/2016
Biogen (BIIB) Pays Ionis Pharma (IONS) $75 Million for Successful Late-Stage Nusinersen Data 8/1/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma 8/1/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA 8/1/2016
Eisai Company (ESALY.PK) Presents Results Of Additional Analysis Of Phase III Study Of Anticancer Agent Halaven At 14th JSMO Annual Meeting Plenary Session 8/1/2016
Sanofi (SNY) And Regeneron (REGN) Announce EMA Acceptance For Review Of Marketing Authorisation Application For Sarilumab 8/1/2016
Otonomy (OTIC) Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial For OTO-104 In Ménière’s Disease Patients 8/1/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In July For Its Phase III Head And Neck Cancer Trial 8/1/2016
AcelRx (ACRX) To Present Initial Results Of Phase 3 Study Of ARX-04 At World Congress Of Mountain & Wilderness Medicine 8/1/2016
More Positive Phase III Data for Pfizer (PFE)'s Xeljanz in Ulcerative Colitis 7/29/2016
First Patient Enrolled In Mallinckrodt (MNK) Phase 3 Terlipressin Trial 7/29/2016
AbbVie (ABBV) Announces Initiation Of Phase 3 Study Of Venetoclax In Patients With Relapsed Or Refractory Multiple Myeloma 7/29/2016
Edge Therapeutics Announces First Patient Treated In Phase III NEWTON 2 Study Of EG-1962 In Adult Patients With Aneurysmal Subarachnoid Hemorrhage 7/29/2016
Quark Pharmaceuticals Inc. Awarded Key Patent For QPI-1007 Ocular Neuroprotectant 7/29/2016
AcelRx (ACRX) Provides Corporate Update And Reports Second Quarter And Six Months 2016 Financial Results 7/29/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
Omeros (OMER) Confirms OMS721 Phase 3 Development Plan With EMA 7/28/2016
Biofrontera AG Receives Favourable CHMP Assessment For Field-Directed Therapy And Files BCC Application 7/28/2016
Amgen (AMGN) Reports Second Quarter 2016 Financial Results 7/28/2016
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016
TauRx Pharma's Much-Watched Alzheimer's Drug Flops in Trial 7/27/2016
Boehringer Ingelheim Halts Two Phase III Trials for Lung Cancer Drug Gilotrif 7/27/2016
CSL Behring Presents Pivotal Efficacy Data For AFSTYLA In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress 7/27/2016
Recro Pharma (REPH) Shares Rocket as Intravenous Painkiller Succeeds in Phase III Trial 7/27/2016
Neurovance Announces Positive Centanafadine Phase 2b Results For Adult ADHD, And Plans For Phase 3 Trials 7/27/2016
Celgene (CELG)'s Revlimid Fails to Extend Survival in Lymphoma Study 7/26/2016
Tokai Pharma (TKAI) to Terminate ARMOR3-SV Clinical Trial, Shares Tank 7/26/2016
Genmab, Inc. (GEN.CO), Johnson & Johnson (JNJ)'s Daratumumab Granted Breakthrough Tag by the FDA 7/26/2016
CSL Behring Presents Phase III Data For IDELVION For Hemophilia B At The World Federation of Hemophilia 2016 World Congress 7/26/2016
Tonix Pharma (TNXP) Initiates Second Pivotal Phase III Clinical Study Of TNX-102 SL In Fibromyalgia 7/26/2016
First Patient Enrolled Under Newly Modified Protocol In CytoDyn (CYDY)’s Phase III PRO 140 Combination Study In HIV 7/26/2016
Astellas (ALPMY) And FibroGen (FGEN) Announce First Patient Treated In Phase III Studies And Positive Phase II Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 7/26/2016
Shire (SHPG) Release: ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation of Hemophilia 7/26/2016
XBiotech (XBIT) Provides Update On Xilonix Phase III Programs In U.S. And EU 7/25/2016
Vtesse Bags Another $17 Million to Support Further Product Development and Expand Ongoing Clinical Trials 7/25/2016
Shire (SHPG) Release: ONIVYDE Receives Positive CHMP Opinion For Treatment Of Patients With Metastatic Adenocarcinoma Of The Pancreas Who Have Progressed Following Gemcitabine Based Therapy 7/25/2016
PharmaEngine, Inc. Announces ONIVYDE Regimen Receives CHMP Positive Opinion For The Treatment Of Metastatic Pancreatic Cancer 7/25/2016
Merrimack (MACK) Announces ONIVYDE Regimen Receives Positive CHMP Opinion In European Union 7/25/2016
CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie (ABBV)'s VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A) 7/25/2016
BeyondSpring Pharmaceuticals Release: Investigator-Sponsored Plinabulin Combination Study For Metastatic Non-Small Cell Lung Cancer Granted FDA Clearance To Enroll Patients 7/25/2016
Aclaris (ACRS) Completes Enrollment Of Phase 3 Pivotal Trials Of A-101 For The Treatment Of Seborrheic Keratosis (SK); Provides Update On Clinical Programs 7/25/2016
Alzheon Presents Positive Results Of ALZ-801 Clinical Studies That Lead To Advancement To Pivotal Phase III Study In Alzheimer's Patients With APOE4/4 Homozygous Genotype 7/25/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Reports Progress In Two Lead Cancer Immunotherapy Programs 7/25/2016
Gilead (GILD)'s Odefsey Successful in Two Phase IIIb Studies 7/22/2016
Sunovion Pharmaceuticals Inc. Announces Results Of Phase III Long-Term Safety Study Showing SUN-101/Eflow® (Glycopyrrolate) Was Well-Tolerated In People With Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 7/22/2016
Data For Merck & Co. (MRK)'s Investigational Once-Daily Formulation Of ISENTRESS (Raltegravir) Show That At Week 48, A Regimen Containing The Once-Daily Dosing Formulation 7/22/2016
Puma Biotech (PBYI) Announces Interim 5-Year Disease Free Survival Data From Phase III Trial Of PB272 (Neratinib) In Extended Adjuvant HER2-Positive Early Stage Breast Cancer (Extenet Trial) 7/22/2016
Amgen (AMGN) And UCB Submit Biologics License Application For Romosozumab To The FDA 7/22/2016
Zafgen (ZFGN) Pinks Slips 34% of Workforce, Scraps Lead Obesity Drug After Deaths 7/21/2016
Amgen (AMGN) And Allergan (AGN) Biosimilar Found as Effective as Genentech (RHHBY)'s Herceptin 7/21/2016
Actinium (ATNM.OB) Calls Investigator Meeting in Dallas 'Successful' 7/20/2016
Biohaven Commences Clinical Testing Of BHV-4157 7/20/2016
Genentech (RHHBY) Receives a Blow After Lymphoma Drug Flunks Phase III Test 7/19/2016
Evoke Pharma (EVOK) Stock Decimated After Late-Stage Trial Miss 7/19/2016
Alcobra (ADHD) Granted European Orphan Drug Designation For Metadoxine In Fragile X Syndrome 7/19/2016
CSL Behring To Present New Data For IDELVION And AFSTYLA At The World Federation of Hemophilia 2016 World Congress 7/19/2016
AstraZeneca PLC (AZN)'s TAGRISSO Met Primary Endpoint in Late-Stage Lung Cancer Trial 7/18/2016
ViiV Healthcare Release: ARIA Study Shows Superior Efficacy Of Triumeq For Treatment-Naïve Women Living With HIV 7/18/2016
Alizé Pharma To Present Results From AZP-531 Phase II Trial In Prader-Willi Syndrome At Two Upcoming Scientific Conferences 7/18/2016
Citius Pharma Completes Feasibility Study Of Investigator Sites For Mino-Lok Phase 3 Trials 7/18/2016
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress 7/18/2016
BioLife Solutions, Inc. (BLFS.OB) Products Embedded In Cook MyoSite Phase 3 Cell Therapy Clinical Trial For Stress Urinary Incontinence 7/18/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data 7/15/2016
European Regulator Calls XBiotech (XBIT)'s Phase III Cancer Data Unreliable 7/15/2016
BeyondSpring Pharmaceuticals Release: Investigator-Sponsored Plinabulin Combination Study For Metastatic Non-Small Cell Lung Cancer Granted FDA Clearance To Enroll Patients 7/14/2016
Pfizer (PFE) Shows Off Final Data from Two Late-Stage Dermatitis Studies 7/13/2016
Nuvo Pharmaceuticals Inc. Announces Pennsaid 2% Phase 3 Trial To Support Regulatory Approvals In The E.U., Canada And Australia 7/13/2016
Good News for Gilead (GILD) as Zydelig Passes Safety Review Test Despite Trial Deaths 7/12/2016
CytRx (CYTR) Craters After Aldoxorubicin Flops in Phase III Trial 7/12/2016
3 Nauseating Clinical Trial Flops of 2016 So Far 7/12/2016
Amgen (AMGN) To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab 7/12/2016
Cipher Pharma (DND.TO) Announces Ozenoxacin Accepted For Review By Health Canada 7/12/2016
Novo Nordisk A/S (NVO) To Present 28 Abstracts At The World Federation Of Hemophilia World Congress In Orlando 7/12/2016
ENGOT And Tesaro (TSRO) Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial 7/11/2016
AbbVie (ABBV) Shows Off Positive HUMIRA Phase III Data in Moderate to Severe Fingernail Psoriasis 7/7/2016
Alexion (ALXN) Release: New Data From Phase III REGAIN Study Of Eculizumab (Soliris) In Patients With Refractory Generalized Myasthenia Gravis (Gmg) Presented At ICNMD Annual Congress 7/7/2016
Janssen R&D And Johnson & Johnson (JNJ) To Provide Webcast Presentation On Phase 3 Data For DARZALEX (Daratumumab) And The Janssen Immuno-Oncology Strategy And Portfolio 7/7/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Bausch & Lomb And Nicox Announce The Publication Of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results In American Journal Of Ophthalmology 7/6/2016
XBiotech (XBIT)'s Colorectal Cancer Drug Claims Fall Apart, Shares Plummet 7/6/2016
Merck & Co. (MRK) And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
FDA Grants Special Protocol Assessment to Advaxis (ADXS)’ Phase III Study Of AXAL In Patients With Cervical Cancer 7/6/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) Initiate Phase III Trial To Evaluate Avelumab As First-Line Treatment For Ovarian Cancer 7/6/2016
RiboMed Biotechnologies, Inc. And Tocagen Inc. Collaborate To Analyze Epigenetic Prognostic Markers, Including MGMT, In Recurrent Brain Tumors 7/6/2016
Ocular Therapeutix (OCUL) To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference 7/6/2016
Teva (TEVA) And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA 7/5/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In June For Its Phase III Head And Neck Cancer Trial 7/5/2016
Merck & Co. (MRK) Release: Results Of Pivotal TAILOR Study Confirm Addition Of Erbitux To FOLFOX Significantly Improves Outcomes In RAS Wild-Type Metastatic Colorectal Cancer 7/1/2016
Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016
Alnylam (ALNY) Reports New Results From Investigational RNAi Therapeutic Programs For Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN) And Cardiomyopathy (hATTR-CM) 7/1/2016
Allergan (AGN) Receives Positive Opinion Through European Decentralised Procedure For BELKYRA (Deoxycholic Acid) For Patients With Submental Fullness 7/1/2016
Array BioPharma (ARRY) Submits Binimetinib New Drug Application To U.S. FDA 7/1/2016
Galena Biopharma  (GALE) Craters and Discontinues Phase III Breast Cancer Vaccine NeuVax 6/30/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal 6/30/2016
Merrimack (MACK) Release: NAPOLI-1 Data Demonstrates ONIVYDE Regimen Maintains Quality Of Life While Improving Overall Survival In Patients With Metastatic Pancreatic Cancer 6/30/2016
Investors Gain Focus as Shire (SHPG) Stock Rises at Positive ADHD Drug News 6/30/2016
Xcovery Announces Initiation Of Phase 3 Trial Of X-396 In ALK+ Non-Small Cell Lung Cancer 6/30/2016
Biofrontera AG Initiates Phase III Trial Of Ameluz In Combination With Daylight-PDT 6/30/2016
Tesaro (TSRO)'s Phase III NOVA Trial of Niraparib Hits Primary Endpoint; NDA and MAA Planned for Q4 2016 6/29/2016
Esperion (ESPR) Falls on Lack of FDA Clarity for Cholesterol Drug 6/29/2016
Omeros (OMER) Announces Completion Of Patient Enrollment In Pediatric Trial Of OMIDRIA 6/29/2016
Anthera Provides Clinical Program Updates For Blisibimod And Sollpura 6/29/2016
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016
Center Point Clinical Services Signs Partnership Agreement With ContraVir 6/29/2016
Phase III Data Show Bayer (BAY)'s Stivarga (Regorafenib) Improved Overall Survival In Previously Treated Patients With Unresectable Liver Cancer 6/28/2016
Tobira’s Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH 6/28/2016
Pfizer (PFE) Release: Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results 6/28/2016
Celyad’s CHART-1 Phase III Shows No Significant Difference on Primary Endpoint 6/28/2016
NewLink Genetics (NLNK) Stock Slides and Company Lays Off 87 After Failed Trial 6/28/2016
AcelRx (ACRX) Completes Patient Enrollment In Remaining Phase 3 Studies Of ARX-04 As A Potential Treatment Of Moderate-To-Severe Acute Pain 6/28/2016
Auris Medical AG (EARS) Completes Enrollment Of Phase 3 TACTT3 Trial With Keyzilen In Acute And Post-Acute Inner Ear Tinnitus 6/28/2016
BeyondSpring Pharmaceuticals's Global Phase III Non-Small Cell Lung Cancer Clinical Trial For Plinabulin Launches In China 6/28/2016
Intensity Therapeutics, Inc. Raises $10 Million To Fund Clinical Supplies Manufacturing And Phase I/II Trials Of INT230-6 6/28/2016
VM BioPharma Announces First Patient Dosed In Phase 3 Study Of Gene Therapy Candidate, VM202, In Painful Diabetic Peripheral Neuropathy 6/27/2016
The Medicines Company (MDCO) Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE 6/27/2016
GW Pharma (GWPH)’s Epidiolex Meets Primary Endpoint in Phase III 6/27/2016
AnGes Terminates Phase III HGF Plasmid, Starts New Plan 6/27/2016
Axsome (AXSM) Added To Russell 3000 And Russell 2000 Indexes 6/27/2016
Teva (TEVA) Receives CHMP Positive Opinion For CINQAERO (Reslizumab) 6/24/2016
Innocoll (INNL) Announces The Completion Of Enrollment In Two Pivotal Phase III Clinical Trials Of COGENZIA For The Treatment Of Diabetic Foot Infections 6/23/2016
Incyte (INCY) Announces First Patient Treated In ECHO-301 Phase 3 Study 6/23/2016
Boston Biomedical Announces First Orphan Drug Designation For Napabucasin In Gastric/GEJ Cancer 6/23/2016
BioCon (BIOCON.NS), Quark Pharmaceuticals Inc. Announce Initiation Of Pivotal Phase II/III Study Of QPI-1007 In Rare Eye Disease In India 6/23/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Merrimack (MACK) To Present New Analyses Of Phase 3 NAPOLI-1 Data At The ESMO 18th World Congress On Gastrointestinal Cancer 6/22/2016
Theravance Biopharma (TBPH) Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study Of The Closed Triple Announced By GlaxoSmithKline (GSK) And Innoviva 6/21/2016



//-->